NCT00615524撤回2 期
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Compare the Efficacy and Tolerability of Pazopanib Administered in Combination With Exemestane Versus Exemestane Plus Placebo in Postmenopausal Subjects With Advanced or Metastatic Hormone Receptor Positive Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Progression free survival
研究概览
简要总结
This study is being conducted to compare the efficacy and safety of exemestane alone or in combination with pazopanib in postmenopausal women who have hormone receptor positive breast cancer and have failed therapy with tamoxifen, anastrazole or letrozole.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Subjects must have measurable disease OR must be evaluable for disease progression
- •Age >/= 18 years.
- •Postmenopausal women
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or
- •Histologically or cytologically confirmed ER and/or PgR positive carcinoma of the breast with unresectable, locally advanced and/or metastatic disease
- •Subjects must have received prior hormonal therapy for the treatment of breast cancer (anastrozole, letrozole, or tamoxifen)
- •Adequate hematologic, hepatic, and renal function
排除标准
- •Prior use of exemestane or pazopanib
- •Premenopausal women
- •Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is progressing in severity.
- •Prior therapy with a VEGF inhibitor.
- •Use of an investigational agent, including an investigational anti-cancer agent, within 28 days or 5 half-lives, whichever is longer, prior to the first dose of investigational product.
- •Evidence of recurrence or active disease from prior malignancy.
- •Clinically significant gastrointestinal abnormalities that may increase the risk for GI bleeding or affect the absorption of the investigational product(s).
- •Presence of uncontrolled infection.
- •History of any major cardiovascular conditions within the past 6 months:
- •Poorly controlled hypertension
- •History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
- •Prior major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer
- •Evidence of active bleeding or bleeding tendency.
结局指标
主要结局
Progression free survival
次要结局
- Safety and tolerability Overall response rate (complete and partial responses) in subjects with measurable disease Overall survival Change in health-related quality of life (HRQL) relative to baseline Biomarkers
研究者
研究点 (1)
Loading locations...
相似试验
终止
3 期
TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)Healthcare WorkersCOVID-19SARS-CoV 2NCT04405271Hospital Italiano de Buenos Aires1,378
已完成
2 期
Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral NeuropathyPainful Diabetic Peripheral NeuropathyNCT05123196Tanabe Pharma Corporation156
已完成
1 期
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLCCarcinoma, Non-Small Cell LungNon-Small-Cell Lung CarcinomaNCT00602030Syndax Pharmaceuticals141
已完成
2 期
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast CancerBreast CancerNCT00767520Bristol-Myers Squibb155
已完成
3 期
Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic RhinitisRhinitis, Allergic, PerennialNCT02182518Boehringer Ingelheim101